The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.
A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.
A retrospective study sought to confirm real-world outcomes of patients with HER2+ breast cancer treated with trastuzumab deruxtecan.
Bayer's Nubeqa gains approval in India for non-chemotherapy treatment of advanced prostate cancer, enhancing patient care ...
Bayer expands Nubeqa in India as a treatment option without chemotherapy for men with metastatic hormone sensitive prostate cancer: Our Bureau, Bengaluru Tuesday, February 24, 202 ...
There's two promising options to make statins tolerable again.
An informational overview of Ivím Health's compounded semaglutide and tirzepatide telehealth program, including GLP-1 ID cost breakdown, weekly provider check-in structure, clinical claims analysis, a ...
By Vijay Kumar Malesu Emerging evidence suggests that microbial metabolites not only regulate endogenous GLP-1 secretion but may also influence therapeutic response to GLP-1 receptor agonists, raising ...
This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...
DoD-Funded Study Accelerates Novel PTSD Mechanism into Trials; Proven Alcohol Safety Profile De-Risks Program for ...
Bacteria in the gut may influence how GLP-1 receptor agonists work. This could help explain why patients do not respond ...